Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.

Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.

The present invention relates to compositions and methods for the treatment of cancer and other diseases associated with mitochondrial dysfunction, including but not limited to, neurodegenerative disease, brain injuries, and certain non-neurological disorders, using a novel compound, 6-chloro-3-(2,4-dichloro-5-methoxyphenyl)-2-mercapto-7-methoxyquinazolin-4(3H)-one, and derivatives thereof.

The present invention relates to compositions and methods for the treatment of cancer and other diseases associated with mitochondrial dysfunction, including but not limited to, neurodegenerative disease, brain injuries, and certain non-neurological disorders, using a novel compound, 6-chloro-3-(2,4-dichloro-5-methoxyphenyl)-2-mercapto-7-methoxyquinazolin-4(3H)-one, and derivatives thereof.

Provided is a 2-heteroaryl aminoquinazolinone derivative, which is a compound represented by formula (1):

##STR00001##

or a pharmaceutically acceptable salt thereof wherein X.sup.1 represents CR.sup.1 or N, X.sup.2 represents CR.sup.2 or N, X.sup.3 represents CR.sup.3 or N, X.sup.4 represents CR.sup.4 or N, Y represents optionally substituted C.sub.1-6 alkyl, an optionally substituted C.sub.3-10 alicyclic group, an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, optionally substituted C.sub.6-10 aryl, or optionally substituted 5- to 10-membered heteroaryl, Z represents optionally substituted 6- to 10-membered heteroaryl, and R.sup.1, R.sup.2, R.sup.3, and R.sup.4 each independently represent a hydrogen atom, halogen, cyano, optionally substituted C.sub.1-6 alkyl, optionally substituted C.sub.1-6 alkoxy, or the like.

This application relates to quinazoline derivatives of formula (I), pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds of formula (I) in the treatment or prevention of a viral infection, of a virus-induced disease, of cancer or of an allergy. In formula (I), R.sub.1 is a C.sub.3-8alkyl, optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, amino, nitrile, ester, amide, C.sub.1-3 alkyl, or C.sub.1-3 alkoxy, the carbon of R.sub.1 bonded to the amine in the 4-position of the quinazoline is in (R)-configuration, R.sub.2 is hydrogen, deuterium, fluorine, chlorine, methyl, methoxy, cyclopropyl, trifluoromethyl, or carboxylic amide, wherein each of methyl, methoxy and cyclopropyl is optionally substituted by one or more substituents independently selected from fluorine and nitrile, R.sub.3 is hydrogen or deuterium, R.sub.4 is hydrogen, deuterium, fluorine, methyl, carboxylic ester, carboxylic amide, nitrile, cyclopropyl, C.sub.4-7 heterocycle, or 5-membered heteroaryl group, wherein each of methyl, cyclopropyl, C.sub.4-7 heterocycle and 5-membered heteroaryl group is optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, or methyl, R.sub.5 is hydrogen, deuterium, fluorine, chlorine, methyl, or methoxy, provided that at least one of R.sub.2, R.sub.3, R.sub.4 and R.sub.5 is not hydrogen. ##STR00001##

This application relates to quinazoline derivatives of formula (I), pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds of formula (I) in the treatment or prevention of a viral infection, of a virus-induced disease, of cancer or of an allergy. In formula (I), R.sub.1 is a C.sub.3-8alkyl, optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, amino, nitrile, ester, amide, C.sub.1-3 alkyl, or C.sub.1-3 alkoxy, the carbon of R.sub.1 bonded to the amine in the 4-position of the quinazoline is in (R)-configuration, R.sub.2 is hydrogen, deuterium, fluorine, chlorine, methyl, methoxy, cyclopropyl, trifluoromethyl, or carboxylic amide, wherein each of methyl, methoxy and cyclopropyl is optionally substituted by one or more substituents independently selected from fluorine and nitrile, R.sub.3 is hydrogen or deuterium, R.sub.4 is hydrogen, deuterium, fluorine, methyl, carboxylic ester, carboxylic amide, nitrile, cyclopropyl, C.sub.4-7 heterocycle, or 5-membered heteroaryl group, wherein each of methyl, cyclopropyl, C.sub.4-7 heterocycle and 5-membered heteroaryl group is optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, or methyl, R.sub.5 is hydrogen, deuterium, fluorine, chlorine, methyl, or methoxy, provided that at least one of R.sub.2, R.sub.3, R.sub.4 and R.sub.5 is not hydrogen. ##STR00001##

A compound of formula I

##STR00001##

wherein A, X, Y, Z, R.sub.1 and R.sub.24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, I.sub.Kur-associated disorders, and other disorders mediated by ion channel function.

A compound of formula I

##STR00001##

wherein A, X, Y, Z, R.sub.1 and R.sub.24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, I.sub.Kur-associated disorders, and other disorders mediated by ion channel function.

Provided herein are compounds of formula (I), pharmaceutical compositions comprising such compounds, and methods of using such compounds through induction of the T helper 1 (Th1) immune response to treat infections, diseases, and disorders. The compounds disclosed herein may also be considered prodrugs and vaccine adjuvants.

##STR00001##